Literature DB >> 32185445

PI-RADS: what is new and how to use it.

Silvina P Dutruel1, Sunil Jeph1, Daniel J A Margolis2, Natasha Wehrli1.   

Abstract

The prostate imaging reporting and data system (PI-RADS) has revolutionized the use of magnetic resonance imaging (MRI) for the management of prostate cancer (PCa). The most recent version 2.1, PI-RADS v2.1, provides specific refinements in the performance, relaxing some recommendations which were not found to be helpful, while reinforcing and clarifying others. The interpretation of T2-weighted imaging (T2WI) in the transition zone (TZ), and the overall assessment of TZ nodules, now allows for a clearer distinction between those which are clearly benign and those which might warrant tissue sampling. Additional changes also resolve discrepancies in T2WI and diffusion-weighted imaging (DWI) of the peripheral zone (PZ). PI-RADS v2.1 is a simpler, more straightforward, and more reproducible method to better communicate between physicians regarding findings on prostate MRI.

Entities:  

Keywords:  Assessment; Cancer; MRI; PI-RADS; Prostate; Reporting

Mesh:

Year:  2020        PMID: 32185445     DOI: 10.1007/s00261-020-02482-x

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  44 in total

Review 1.  The expanding role of MRI in prostate cancer.

Authors:  Gillian Murphy; Masoom Haider; Sangeet Ghai; Boraiah Sreeharsha
Journal:  AJR Am J Roentgenol       Date:  2013-12       Impact factor: 3.959

2.  MRI and ultrasonography in staging prostate cancer.

Authors:  T C Gasser; K Streule; A Nidecker; M Rist
Journal:  N Engl J Med       Date:  1991-02-14       Impact factor: 91.245

Review 3.  Multiparametric MRI: An Opportunity for Focal Therapy of Prostate Cancer.

Authors:  Brian Calio; Matthew Kasson; Doraneh Sugano; Michael Ortman; Krishnanath Gaitonde; Sadhna Verma; Abhinav Sidana
Journal:  Semin Roentgenol       Date:  2018-06-06       Impact factor: 0.800

4.  Staging prostate cancer with MR imaging.

Authors:  E H Sumers
Journal:  Radiology       Date:  1993-06       Impact factor: 11.105

5.  Accuracy of multiparametric magnetic resonance imaging in confirming eligibility for active surveillance for men with prostate cancer.

Authors:  Lambros Stamatakis; M Minhaj Siddiqui; Jeffrey W Nix; Jennifer Logan; Soroush Rais-Bahrami; Annerleim Walton-Diaz; Anthony N Hoang; Srinivas Vourganti; Hong Truong; Brian Shuch; Howard L Parnes; Baris Turkbey; Peter L Choyke; Bradford J Wood; Richard M Simon; Peter A Pinto
Journal:  Cancer       Date:  2013-07-02       Impact factor: 6.860

6.  Prospective evaluation of 3-T MRI performed before initial transrectal ultrasound-guided prostate biopsy in patients with high prostate-specific antigen and no previous biopsy.

Authors:  Byung Kwan Park; Jong Wook Park; Seo Yong Park; Chan Kyo Kim; Hyun Moo Lee; Seong Soo Jeon; Seong Il Seo; Byong Chang Jeong; Han Yong Choi
Journal:  AJR Am J Roentgenol       Date:  2011-11       Impact factor: 3.959

Review 7.  The Emerging Role of MRI in Prostate Cancer Active Surveillance and Ongoing Challenges.

Authors:  Tristan Barrett; Masoom A Haider
Journal:  AJR Am J Roentgenol       Date:  2016-10-11       Impact factor: 3.959

8.  Diagnostic Pathway with Multiparametric Magnetic Resonance Imaging Versus Standard Pathway: Results from a Randomized Prospective Study in Biopsy-naïve Patients with Suspected Prostate Cancer.

Authors:  Francesco Porpiglia; Matteo Manfredi; Fabrizio Mele; Marco Cossu; Enrico Bollito; Andrea Veltri; Stefano Cirillo; Daniele Regge; Riccardo Faletti; Roberto Passera; Cristian Fiori; Stefano De Luca
Journal:  Eur Urol       Date:  2016-08-27       Impact factor: 20.096

9.  Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy.

Authors:  M Minhaj Siddiqui; Soroush Rais-Bahrami; Hong Truong; Lambros Stamatakis; Srinivas Vourganti; Jeffrey Nix; Anthony N Hoang; Annerleim Walton-Diaz; Brian Shuch; Michael Weintraub; Jochen Kruecker; Hayet Amalou; Baris Turkbey; Maria J Merino; Peter L Choyke; Bradford J Wood; Peter A Pinto
Journal:  Eur Urol       Date:  2013-06-12       Impact factor: 20.096

10.  MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis.

Authors:  Veeru Kasivisvanathan; Antti S Rannikko; Marcelo Borghi; Valeria Panebianco; Lance A Mynderse; Markku H Vaarala; Alberto Briganti; Lars Budäus; Giles Hellawell; Richard G Hindley; Monique J Roobol; Scott Eggener; Maneesh Ghei; Arnauld Villers; Franck Bladou; Geert M Villeirs; Jaspal Virdi; Silvan Boxler; Grégoire Robert; Paras B Singh; Wulphert Venderink; Boris A Hadaschik; Alain Ruffion; Jim C Hu; Daniel Margolis; Sébastien Crouzet; Laurence Klotz; Samir S Taneja; Peter Pinto; Inderbir Gill; Clare Allen; Francesco Giganti; Alex Freeman; Stephen Morris; Shonit Punwani; Norman R Williams; Chris Brew-Graves; Jonathan Deeks; Yemisi Takwoingi; Mark Emberton; Caroline M Moore
Journal:  N Engl J Med       Date:  2018-03-18       Impact factor: 176.079

View more
  2 in total

1.  Impact of measurement method on interobserver variability of apparent diffusion coefficient of lesions in prostate MRI.

Authors:  Hiroaki Takahashi; Kotaro Yoshida; Akira Kawashima; Nam Ju Lee; Adam T Froemming; Daniel A Adamo; Ashish Khandelwal; Candice W Bolan; Matthew T Heller; Robert P Hartman; Bohyun Kim; Kenneth A Philbrick; Rickey E Carter; Lance A Mynderse; Mitchell R Humphreys; Jason C Cai; Naoki Takahashi
Journal:  PLoS One       Date:  2022-05-23       Impact factor: 3.752

Review 2.  PI-RADSv2.1: Current status.

Authors:  Stephanie M Walker; Barış Türkbey
Journal:  Turk J Urol       Date:  2020-10-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.